Logo

The Relief of Nociceptive Pain Induced by Panitumumab Could be Sustainable during Chemotherapy

Authors

  • Shu Yuasa

    Department of Pharmacy, Nagoya Memorial Hospital, Nagoya, Japan

  • Ryuichi Furuta

    Department of Medical Oncology, Nagoya Memorial Hospital, Nagoya, Japan

  • Megumi Kabeya

    Department of Pharmacy, Nagoya Memorial Hospital, Nagoya, Japan and Palliative Care Team, Nagoya Memorial Hospital, Nagoya, Japan

  • Yuko Shirokawa

    Nursing Department, Nagoya Memorial Hospital, Nagoya, Japan

  • Satoshi Hibi

    Department of Pharmacy, Nagoya Memorial Hospital, Nagoya, Japan

  • Seiji Nagao

    Department of Medical Examination, Nagoya Memorial Hospital, Japan

  • Shozo Togawa

    Department of Gastroenterology, Nagoya Memorial Hospital, Nagoya, Japan

  • Satoshi Kayukawa

    Department of Clinical Oncology, Nagoya Memorial Hospital, Japan

  • Kenji Ina

    Department of Geriatric Medicine, Shinseikai Dai-ichi Hospital, Nagoya Japan
    https://orcid.org/0000-0001-8646-0611

DOI:

https://doi.org/10.30683/1927-7229.2024.13.09

Keywords:

Panitumumab, cancer-related pain, pain relief, nociceptive pain, visceral pain, somatic pain, neuropathic pain, colorectal cancer

Abstract

Anti-epidermal growth factor receptor (EGFR) antibodies and tyrosine kinase inhibitors, which are molecular-targeted drugs used in cancer treatment, are suspected to have analgesic effects on cancer-related pain. The relieving effect of EGFR inhibitors on neuropathic pain has been described to persist for approximately 20 days in patients with colorectal cancer. Since the administration of panitumumab, ananti-EGFR antibody, is repeated every 14 days, its relieving effect on cancer-related pain should be maintained until the next administration. To test this hypothesis, we investigated the chronological changes in symptoms before and two and 14 days after administration. A retrospective study using electrical patient charts demonstrated that the analgesic effects of panitumumab sustained in 8 out of ten patients with colorectal cancer (80%) until the start of next cycle of chemotherapy. The relief of nociceptive pain can be maintained in most of the patients during chemotherapy by repeated use of this agent, once pain relief has been achieved.

References

Douillard JY, Siena S, Cassidy J, et al. Randomized phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first line treatment in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2010; 28: 4697-705. https://doi.org/10.1200/JCO.2009.27.4860

Martin LJ, Smith SB, Khoutorsky A, et al. Epiregulin and EGFR interactions are involved in pain processing. J Clin Invest 2017; 127: 3353-66. https://doi.org/10.1172/JCI87406

Verma V, Khoury S, Parisien M, et al. The dichomatous role of epiregulin in pain. Pain 2020; 161: 1052-64. https://doi.org/10.1097/j.pain.0000000000001792

Hirsh V, Cadranel J, Cong XJ, et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol 2013; 8: 229-37. https://doi.org/10.1097/JTO.0b013e3182773fce

Kersten C, Cameron MG, Laird B, Mjaland S. Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain. Br J Anaesthesia 2015; 115: 761-767. https://doi.org/10.1093/bja/aev326

Kersten C, Cameron MG, Bailey AG, et al. Relief of neuropathic pain through epidermal growth factor receptor inhibition: A randomized proof-of-concept trial. Pain Med 2019; 20: 2495-2505. https://doi.org/10.1093/pm/pnz101

Kersten C, Cameronb MG. Cetuximab alleviates neuropathic pain despite tumour progression. BMJ Case Reports 2012. pii: bcr1220115374. https://doi.org/10.1136/bcr.12.2011.5374

Yuasa S, Kabeya M, Furuta R, et al. A case of sigmoid colon cancer in which somatic pain was rapidly alleviated after panitumumab administration despite tumor progression. J Anal Oncol 2016; 5: 38-41. https://doi.org/10.6000/1927-7229.2016.05.01.5

Yuasa S, Kabeya M, Furuta R, et al, Retrospective comparison of changes in cancer pain and chronic peripheral neuropathy induced by oxaliplatin before and after administration of panitumumab and bevacizumab. J Anal Oncol, 2022; 11: 40-44. https://doi.org/10.30683/1927-7229.2022.11.06

Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413: 203-10. https://doi.org/10.1038/35093019

Borges JP, Mekhail K, Fairn GD, Antonescu CN, Steinberg BE. Modulation of pathological pain by epidermal growth factor receptor. Front Pharmacol 2021; 12: 642820. https://doi.org/10.3389/fphar.2021.642820

Zhuang ZY, Gerner P, Woolf C, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005; 114: 149-59. https://doi.org/10.1016/j.pain.2004.12.022

Puig S, Donica CL, Gutstein HB. EGFR signaling causes morphine tolerance and mechanical sensitization in rats. eNeuro. 2020; 7: ENEURO.0460-18.2020. https://doi.org/10.1523/ENEURO.0460-18.2020

Santi MD, Zhang M, Liu N, et al. Repurposing EGFR inhibitors for oral cancer pain and opioid tolerance. Pharmaceuticals (Basel) 2023; 16: 1558. https://doi.org/10.3390/ph16111558

Cameron MG, Kersten C. Prospective case series of neuropathic cancer pain in patients treated with an EGFR-inhibitor. Palliative Medicine 2022; 36: 1154-1162. https://doi.org/10.1177/02692163221102003

Japanese society for palliative medicine, Clinical guideline for cancer pain management third edition 2020, pp22-26, Kanehara & Co. Ltd, Tokyo Japan.

Ries DJ, Cullum RL. Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol 2014; 28: 49-56. https://doi.org/10.1016/j.semcdb.2014.03.005

Downloads

Published

2024-12-12

Issue

Vol. 13 (2024)

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

The Relief of Nociceptive Pain Induced by Panitumumab Could be Sustainable during Chemotherapy. (2024). Journal of Analytical Oncology, 13, 59-63. https://doi.org/10.30683/1927-7229.2024.13.09

Similar Articles

161-170 of 182

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)